Internal Medicine, Rheumatology · Van Nuys, CA
NPI
1851372288
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
15243 Vanowen St, Suite 306
Van Nuys, CA, 91405
Phone (818) 781-0232
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
73,098 services
Medicare patients, 2024
271
Average age 77
Drug cost, 2024
$1.9M
1,772 prescriptions
Company payments, 2025
$17
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Charles E Weidmann was code J3111 (injection, romosozumab-aqqg, 1 mg), 9,292 times for 17 patients. In total Charles E Weidmann billed 73,098 services in 133 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-01-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 9,292 | 17 | $8.52 | $79K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 7,117 | 21 | $33.39 | $238K |
| J0897 Injection, denosumab, 1 mg | Office | 4,610 | 118 | $20.17 | $93K |
| J7329 Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg | Office | 3,204 | 33 | $5.72 | $18K |
| 86235 Immunoassay | Office | 1,821 | 133 | $17.57 | $32K |
| 36415 Venipuncture Blood Collection | Office | 1,531 | 266 | $8.65 | $13K |
| 99214 Office E&M - Established | Office | 1,316 | 236 | $100.10 | $132K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,307 | 180 | $0.77 | $1,001 |
| 85025 Blood Count | Office | 1,001 | 237 | $7.61 | $7,618 |
| 86140 Clinical Chemistry | Office | 998 | 237 | $5.09 | $5,077 |
| 85651 Clinical Chemistry | Office | 998 | 237 | $4.19 | $4,179 |
| 80053 Clinical Chemistry | Office | 994 | 236 | $10.36 | $10K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 747 | 14 | $23.97 | $18K |
| 84100 Clinical Chemistry | Office | 581 | 222 | $4.65 | $2,702 |
| 83735 Clinical Chemistry | Office | 579 | 222 | $6.58 | $3,811 |
By year: 2022 $953K for 52,951 services; 2023 $1.0M for 57,445 services; 2024 $1.1M for 73,098 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 86235 Immunoassay | 1,821 | 133 | $17.57 | $32K |
| 36415 Venipuncture Blood Collection | 1,531 | 266 | $8.65 | $13K |
| 85025 Blood Count | 1,001 | 237 | $7.61 | $7,618 |
| 86140 Clinical Chemistry | 998 | 237 | $5.09 | $5,077 |
| 85651 Clinical Chemistry | 998 | 237 | $4.19 | $4,179 |
| 80053 Clinical Chemistry | 994 | 236 | $10.36 | $10K |
| 84100 Clinical Chemistry | 581 | 222 | $4.65 | $2,702 |
| 83735 Clinical Chemistry | 579 | 222 | $6.58 | $3,811 |
| 82306 Clinical Chemistry | 449 | 219 | $29.01 | $13K |
| 83970 Clinical Chemistry | 369 | 184 | $40.45 | $15K |
Medicare prescription drug claims, 2024
In 2024, the drug Charles E Weidmann prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 160 prescriptions and refills. In total Charles E Weidmann wrote 1,772 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 160 | 160 | 26 | $4,131 |
| Prolia Denosumab | 132 | 792 | 83 | $213K |
| Orencia Abatacept/Maltose | 121 | 122 | 13 | $502K |
| Gabapentin Generic | 106 | 156 | 24 | $1,570 |
| Methotrexate Methotrexate Sodium | 103 | 203 | 26 | $2,795 |
| Actemra Tocilizumab | 86 | 86 | Under 11 | $211K |
| Evenity (2 Syringes) Romosozumab-Aqqg | 72 | 72 | 11 | $172K |
| Prednisone Generic | 64 | 103 | 22 | $653 |
| Duloxetine Hcl Generic | 63 | 107 | 12 | $1,069 |
| Diclofenac Sodium Generic | 54 | 58 | 17 | $1,813 |
| Pregabalin Generic | 53 | 73 | Under 11 | $1,098 |
| Inflectra Infliximab-Dyyb | 51 | 56 | Under 11 | $307K |
| Celecoxib Generic | 46 | 104 | 17 | $2,047 |
| Remicade Infliximab | 36 | 37 | Under 11 | $189K |
| Alprazolam Generic | 34 | 34 | Under 11 | $163 |
Brand drugs: - claims; generic drugs: 1,163 claims; opioid claims: 212.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Charles E Weidmann $17 ($17 in general payments such as food, travel and fees) from 1 company. The largest payer was GlaxoSmithKline, LLC. with $17.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 1 | $17 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.